982-P: A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-982-P
- By:
- Publication type:
- Article